Johns Hopkins University researchers have developed a hydrogel that combines anticancer drugs and antibodies to cure 100% of mice with aggressive brain cancer, glioblastoma, offering new hope for patients with the deadliest brain tumors.
Researchers at Johns Hopkins University have developed a new hydrogel that cured glioblastoma in 100% of mice with aggressive brain cancer. The hydrogel consists of an anticancer drug and an antibody that, when applied to the brain after the surgical removal of a tumor, can reach areas that surgery might miss and current drugs struggle to access, killing lingering cancer cells and suppressing tumor growth. The gel also seems to activate an immune response, helping the body fight against glioblastoma without additional medication. Although surgery is still essential for this approach, the hydrogel offers new hope for glioblastoma patients. The results of the study were published in Proceedings of the National Academy of Sciences.